You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

The Effect of St John's Wort on the Pharmacodynamic Response of Clopidogrel in Hyporesponsive Volunteers and Patients: Increased Platelet Inhibition by Enhancement of CYP3A4 Metabolic Activity

Lau, Wei C MD*; Welch, Terrence D MD†; Shields, Theresa BSN, RN*; Rubenfire, Melvyn MD†; Tantry, Udaya S PhD‡; Gurbel, Paul A MD‡

Journal of Cardiovascular Pharmacology:
doi: 10.1097/FJC.0b013e3181ffe8d0
Original Article
Abstract

Clopidogrel is metabolically activated by cytochrome P450 (CYP) isoenzymes. We evaluated whether St. John's wort (SJW), a CYP2C19 and CYP3A4 inducer, enhances the pharmacodynamic response of clopidogrel. Volunteers (n = 45) were screened for clopidogrel hyporesponsiveness after a 300-mg load. After a 7-day washout, hyporesponders (n = 10) received 14 days of SJW (300 mg 3 times a day) followed by a second 300-mg clopidogrel. Platelet aggregation was measured at 0, 2, 4, and 6 hours postloading; hepatic CYP3A4 activity was simultaneously determined at 0 and 4 hours by the erythromycin breath test. A prospective, randomized, double-blind pilot study was conducted in postcoronary stent patients (n = 85) on clopidogrel 75 mg/d screened for clopidogrel hyporesponsiveness. Hyporesponders (n = 20) were randomized to SJW (n = 10) or placebo (n = 10); platelet aggregation was measured before and after 14 days of therapy. In volunteers, SJW decreased platelet aggregation (59% ± 14% vs. 40% ± 15% at 2 hours, P = 0.02; 56% ± 10% vs. 44% ± 13% at 4 hours, P < 0.03; and 55% ± 14% vs. 37% ± 14% at 6 hours, P = 0.01) and increased CYP3A4 activity (2.1% ± 0.4% 14CO2 exhaled per hour before vs. 2.9% ± 0.6% 14CO2 exhaled per hour after SJW, P = 0.002). In patients, SJW decreased platelet reactivity (226 ± 39 vs. 185 ± 49 P2Y12 reactivity units, P = 0.0002) and increased platelet inhibition (23% ± 11% vs. 41% ± 16%, P = 0.002). SJW may be a future therapeutic option to increase CYP metabolic activity and antiplatelet effect of clopidogrel in hyporesponders.

Author Information

From the *Cardiovascular Center, Department of Anesthesiology, and †Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI; and ‡Sinai Center for Thrombosis Research, Sinai Hospital of Baltimore, Baltimore, MD.

Received for publication September 9, 2010; accepted October 1, 2010.

Supported by General Clinical Research Center, #M01-RR00042, University of Michigan, McKay Cardiovascular Center Grant, University of Michigan, Cardiovascular Inaugural Center Grant, University of Michigan CVC.

The authors report no conflicts of interest.

Reprints: Wei C. Lau, MD, Department of Anesthesiology, University of Michigan Health System, University of Michigan, 4172 Cardiovascular Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109-5861 (e-mail: weiclau@umich.edu).

© 2011 Lippincott Williams & Wilkins, Inc.